# Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance

> **NCT03057561** · NA · COMPLETED · sponsor: **The Methodist Hospital Research Institute** · enrollment: 120 (actual)

## Conditions studied

- Coronary Artery Disease
- Cardiomyopathy

## Interventions

- **DRUG:** Cardiac MRI taken using contrast agent, Dotarem® (Gd-DOTA)
- **DRUG:** Cardiac MRI with contrast agent, Gadovist

## Key facts

- **NCT ID:** NCT03057561
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-06-30
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03057561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03057561, "Efficacy of Dotarem® (Gd-DOTA) Versus Gadovist® (Gd-DO3A-butrol) for Late Gadolinium Enhancement Cardiac Magnetic Resonance". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT03057561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*